

# Guy Griebel

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5292755/guy-griebel-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

138  
papers

11,459  
citations

56  
h-index

105  
g-index

166  
ext. papers

12,259  
ext. citations

5.7  
avg. IF

6.15  
L-index

#	Paper	IF	Citations
138	Measuring normal and pathological anxiety-like behaviour in mice: a review. <i>Behavioural Brain Research</i> , <b>2001</b> , 125, 141-9	3.4	651
137	Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. <i>Biological Psychiatry</i> , <b>2008</b> , 64, 293-301	7.9	413
136	Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 6370-5	11.5	407
135	5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research <b>1995</b> , 65, 319-95		374
134	Antidepressants recruit new neurons to improve stress response regulation. <i>Molecular Psychiatry</i> , <b>2011</b> , 16, 1177-88	15.1	347
133	Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2001</b> , 25, 205-18	9	339
132	Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice. <i>Psychopharmacology</i> , <b>2000</b> , 148, 164-70	4.7	339
131	Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. <i>Trends in Pharmacological Sciences</i> , <b>2003</b> , 24, 580-8	13.2	335
130	Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. <i>Molecular Psychiatry</i> , <b>2004</b> , 9, 278-86, 224	15.1	260
129	50 years of hurdles and hope in anxiolytic drug discovery. <i>Nature Reviews Drug Discovery</i> , <b>2013</b> , 12, 667-87.1	14.1	259
128	Risk assessment as an evolved threat detection and analysis process. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2011</b> , 35, 991-8	9	243
127	SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. <i>Neuropsychopharmacology</i> , <b>2007</b> , 32, 17-34	8.7	228
126	4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propyl)-3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2002</b> , 301, 333-45	4.7	220
125	Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. <i>Biological Psychiatry</i> , <b>2005</b> , 57, 261-7	7.9	217
124	Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). <i>Neuropsychopharmacology</i> , <b>2005</b> , 30, 145-55	8.7	214
123	Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N-carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2002</b> , 300, 1122-30	4.7	201
122	Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. <i>Neuropsychopharmacology</i> , <b>2005</b> , 30, 1963-85	8.7	194

121	The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic. <i>European Journal of Pharmacology</i> , <b>2003</b> , 463, 97-116	5.3	193
120	Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. <i>Psychopharmacology</i> , <b>1998</b> , 138, 55-66	4.7	183
119	Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. <i>Neuroscience and Biobehavioral Reviews</i> , <b>1997</b> , 21, 783-9	9	182
118	Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2003</b> , 27, 625-31	5.5	175
117	SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. <i>Neuropsychopharmacology</i> , <b>2007</b> , 32, 1-16	8.7	165
116	Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. <i>Pharmacology Biochemistry and Behavior</i> , <b>1997</b> , 57, 817-27	3.9	150
115	Conditioning and residual emotionality effects of predator stimuli: some reflections on stress and emotion. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2003</b> , 27, 1177-85	5.5	150
114	Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. <i>Neuropsychopharmacology</i> , <b>2009</b> , 34, 1363-80	8.7	149
113	Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?. <i>Nature Reviews Drug Discovery</i> , <b>2012</b> , 11, 462-78	64.1	144
112	Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? <b>1999</b> , 82, 1-61		140
111	Behavioral and neurochemical changes following predatory stress in mice. <i>Neuropharmacology</i> , <b>2001</b> , 41, 400-8	5.5	122
110	CB1 receptor antagonists for the treatment of nicotine addiction. <i>Pharmacology Biochemistry and Behavior</i> , <b>2005</b> , 81, 387-95	3.9	113
109	Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. <i>Psychopharmacology</i> , <b>1994</b> , 113, 463-70	4.7	110
108	A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety. <i>Neuropharmacology</i> , <b>1997</b> , 36, 793-802	5.5	109
107	Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415. <i>Neuropsychopharmacology</i> , <b>2005</b> , 30, 35-42	8.7	99
106	Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. <i>Psychopharmacology</i> , <b>1995</b> , 120, 57-66	4.7	94
105	Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. <i>European Journal of Pharmacology</i> , <b>2004</b> , 497, 49-53	5.3	93
104	Some critical determinants of the behaviour of rats in the elevated plus-maze. <i>Behavioural Processes</i> , <b>1993</b> , 29, 37-47	1.6	93

103	Orphanin FQ, a novel neuropeptide with anti-stress-like activity. <i>Brain Research</i> , <b>1999</b> , 836, 221-4	3.7	91
102	Further evidence that the mouse defense test battery is useful for screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam. <i>Neuropharmacology</i> , <b>1995</b> , 34, 1625-33	5.5	86
101	Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals. <i>Stress</i> , <b>2003</b> , 6, 199-206	3	85
100	Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. <i>Neuropsychopharmacology</i> , <b>2008</b> , 33, 574-87	8.7	84
99	Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. <i>Pharmacology Biochemistry and Behavior</i> , <b>2008</b> , 91, 47-58	3.9	81
98	4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2008</b> , 304, 222-232	4.7	81
97	AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamsters. <i>Pharmacology Biochemistry and Behavior</i> , <b>2005</b> , 80, 189-94	3.9	78
96	Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. <i>Current Pharmaceutical Design</i> , <b>2005</b> , 11, 1549-59	3.3	78
95	Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents. <i>Scientific Reports</i> , <b>2015</b> , 5, 7642	4.9	75
94	Behavioral effects of acute and chronic fluoxetine in Wistar-Kyoto rats. <i>Physiology and Behavior</i> , <b>1999</b> , 67, 315-20	3.5	72
93	New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes. <i>Psychopharmacology</i> , <b>1999</b> , 146, 205-13	4.7	71
92	Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats. <i>Psychopharmacology</i> , <b>2006</b> , 187, 237-44	4.7	68
91	The effects of compounds varying in selectivity as 5-HT(1A) receptor antagonists in three rat models of anxiety. <i>Neuropharmacology</i> , <b>2000</b> , 39, 1848-57	5.5	68
90	Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. <i>Psychopharmacology</i> , <b>2009</b> , 202, 385-96	4.7	67
89	Benzodiazepine and serotonergic modulation of antipredator and conspecific defense. <i>Neuroscience and Biobehavioral Reviews</i> , <b>1998</b> , 22, 597-612	9	66
88	SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms. <i>CNS Neuroscience &amp; Therapeutics</i> , <b>2003</b> , 9, 3-20		62
87	Gender bias in the preclinical psychopharmacology of anxiety: male models for (predominantly) female disorders. <i>Journal of Psychopharmacology</i> , <b>1995</b> , 9, 79-82	4.6	61
86	The vasopressin V1b receptor as a therapeutic target in stress-related disorders. <i>CNS and Neurological Disorders</i> , <b>2003</b> , 2, 191-200		60

85	Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils. <i>Pharmacology Biochemistry and Behavior</i> , <b>2006</b> , 83, 533-9	3.9	57
84	Comparison of the behavioural effects of an adenosine A1/A2-receptor antagonist, CGS 15943A, and an A1-selective antagonist, DPCPX. <i>Psychopharmacology</i> , <b>1991</b> , 103, 541-4	4.7	57
83	Behavioral profile of the 5HT1A receptor antagonist (S)-UH-301 in rodents and monkeys. <i>Brain Research Bulletin</i> , <b>1992</b> , 29, 901-4	3.9	57
82	An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders. <i>CNS Neuroscience &amp; Therapeutics</i> , <b>2005</b> , 11, 53-68		56
81	The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. <i>Journal of Clinical Psychiatry</i> , <b>2012</b> , 73, 1403-11	4.6	56
80	Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels. <i>Neuropharmacology</i> , <b>1998</b> , 37, 927-35	5.5	54
79	Evidence that the behaviors in the Mouse Defense Test Battery relate to different emotional states: a factor analytic study. <i>Physiology and Behavior</i> , <b>1996</b> , 60, 1255-60	3.5	54
78	Pharmacological studies on synthetic flavonoids: comparison with diazepam. <i>Neuropharmacology</i> , <b>1999</b> , 38, 965-77	5.5	53
77	SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats. <i>Neuropharmacology</i> , <b>2004</b> , 46, 1121-9	5.5	52
76	Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. <i>Neuropsychopharmacology</i> , <b>2009</b> , 34, 1753-63	8.7	51
75	Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat. <i>Pharmacology Biochemistry and Behavior</i> , <b>2005</b> , 82, 223-7	3.9	51
74	Predator-elicited flight responses in Swiss-Webster mice: an experimental model of panic attacks. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>1996</b> , 20, 185-205	5.5	50
73	Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. <i>Pharmacology Biochemistry and Behavior</i> , <b>2008</b> , 89, 36-45	3.9	48
72	Behavioural profiles in the mouse defence test battery suggest anxiolytic potential of 5-HT(1A) receptor antagonists. <i>Psychopharmacology</i> , <b>1999</b> , 144, 121-30	4.7	48
71	Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents. <i>Psychopharmacology</i> , <b>2001</b> , 158, 241-51	4.7	47
70	An ethopharmacological analysis of selective activation of 5-HT1A receptors: the mouse 5-HT1A syndrome. <i>Pharmacology Biochemistry and Behavior</i> , <b>1997</b> , 57, 897-908	3.9	46
69	Optogenetics to study the circuits of fear- and depression-like behaviors: a critical analysis. <i>Pharmacology Biochemistry and Behavior</i> , <b>2014</b> , 122, 144-57	3.9	45
68	Genetic differences in the mouse defense test battery. <i>Aggressive Behavior</i> , <b>1997</b> , 23, 19-31	2.8	45

67	SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. <i>Psychopharmacology</i> , <b>2005</b> , 181, 134-44	4.7	45
66	5-HT1A agonists modulate mouse antipredator defensive behavior differently from the 5-HT2A antagonist pirenperone. <i>Pharmacology Biochemistry and Behavior</i> , <b>1995</b> , 51, 235-44	3.9	44
65	The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents. <i>Scientific Reports</i> , <b>2018</b> , 8, 2416	4.9	42
64	Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression. <i>Pharmacology Biochemistry and Behavior</i> , <b>2008</b> , 89, 623-6	3.9	42
63	Acute inescapable stress exposure induces long-term sleep disturbances and avoidance behavior: a mouse model of post-traumatic stress disorder (PTSD). <i>Behavioural Brain Research</i> , <b>2011</b> , 221, 149-54	3.4	41
62	CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviours. <i>Behavioural Pharmacology</i> , <b>1997</b> , 8, 549-60	2.4	41
61	Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugs. <i>Neuropsychopharmacology</i> , <b>2005</b> , 30, 1996-2005	8.7	41
60	Contribution of GABAA receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one]. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2005</b> , 313, 1118-25	4.7	39
59	Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling. <i>Psychopharmacology</i> , <b>2007</b> , 194, 161-71	4.7	37
58	Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat. <i>Neuropsychopharmacology</i> , <b>2006</b> , 31, 2180-7	8.7	37
57	Comparison of the pharmacological properties of classical and novel BZ-omega receptor ligands. <i>Behavioural Pharmacology</i> , <b>1999</b> , 10, 483-95	2.4	37
56	SAR110894, a potent histamine H <sub>1</sub> receptor antagonist, displays procognitive effects in rodents. <i>Pharmacology Biochemistry and Behavior</i> , <b>2012</b> , 102, 203-14	3.9	36
55	The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. <i>Neuropsychopharmacology</i> , <b>2010</b> , 35, 416-27	8.7	36
54	Neuropeptides in psychiatric diseases: an overview with a particular focus on depression and anxiety disorders. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2006</b> , 5, 135-45	2.6	36
53	The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodents. <i>Scientific Reports</i> , <b>2019</b> , 9, 18045	4.9	36
52	SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidiny]-2-methylpiperazine) is a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2002</b> , 303, 1180-8	4.7	35
51	m-Chlorophenylpiperazine enhances neophobic and anxious behaviour in mice. <i>NeuroReport</i> , <b>1991</b> , 2, 627-9	1.7	35
50	Behavioral effects of rolipram and structurally related compounds in mice: behavioral sedation of cAMP phosphodiesterase inhibitors. <i>Pharmacology Biochemistry and Behavior</i> , <b>1991</b> , 39, 321-3	3.9	35



49	Anxiolytic-like effects of a selective 5-HT1A agonist, S20244, and its enantiomers in mice. <i>NeuroReport</i> , <b>1992</b> , 3, 84-6	1.7	35
48	Defensive responses to predator threat in the rat and mouse. <i>Current Protocols in Neuroscience</i> , <b>2005</b> , Chapter 8, Unit 8.19	2.7	34
47	Further evidence for differences between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands in murine models of "state" and "trait" anxiety. <i>Neuropharmacology</i> , <b>1996</b> , 35, 1081-91	5.5	34
46	Effects of the CRF1 antagonist SSR125543A on aggressive behaviors in hamsters. <i>Pharmacology Biochemistry and Behavior</i> , <b>2004</b> , 77, 465-9	3.9	33
45	Deep brain stimulation in treatment-resistant depression in mice: comparison with the CRF1 antagonist, SSR125543. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2013</b> , 40, 213-20	5.5	32
44	Beta-CCT, a selective BZ-omega1 receptor antagonist, blocks the anti-anxiety but not the amnesic action of chlordiazepoxide in mice. <i>Behavioural Pharmacology</i> , <b>2000</b> , 11, 125-31	2.4	32
43	Mice deficient in cryptochrome 1 (cry1 (-/-)) exhibit resistance to obesity induced by a high-fat diet. <i>Frontiers in Endocrinology</i> , <b>2014</b> , 5, 49	5.7	31
42	Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents. <i>Journal of Psychopharmacology</i> , <b>1998</b> , 12, 356-65	4.6	31
41	AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. <i>Psychopharmacology</i> , <b>2011</b> , 215, 149-63	4.7	30
40	Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2001</b> , 25, 619-26	9	30
39	The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia. <i>Scientific Reports</i> , <b>2016</b> , 6, 35320	4.9	29
38	Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs. <i>Psychopharmacology</i> , <b>1997</b> , 131, 180-6	4.7	27
37	Long-term impaired memory following predatory stress in mice. <i>Physiology and Behavior</i> , <b>2006</b> , 87, 45-50	3.5	27
36	Discriminative stimulus effects of drugs acting at GABA(A) receptors: differential profiles and receptor selectivity. <i>Pharmacology Biochemistry and Behavior</i> , <b>1999</b> , 64, 269-73	3.9	27
35	Anxiolytic and sedative effects of 5-HT1A ligands, 8-OH-DPAT and MDL 73005EF, in mice. <i>NeuroReport</i> , <b>1990</b> , 1, 267-70	1.7	26
34	Implication of beta3-adrenoceptors in the antidepressant-like effects of amibegron using ADRB3 knockout mice in the chronic mild stress. <i>Behavioural Brain Research</i> , <b>2010</b> , 206, 310-2	3.4	24
33	Phencyclidine decreases tickling-induced 50-kHz ultrasound vocalizations in juvenile rats: a putative model of the negative symptoms of schizophrenia?. <i>Behavioural Pharmacology</i> , <b>2013</b> , 24, 543-51	2.4	23
32	The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice. <i>Pharmacology Biochemistry and Behavior</i> , <b>2011</b> , 98, 425-31	3.9	23

31	Serenics fluprazine (DU 27716) and eltoprazine (DU 28853) enhance neophobic and emotional behaviour in mice. <i>Psychopharmacology</i> , <b>1990</b> , 102, 498-502	4.7	21
30	Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?. <i>Pharmacology &amp; Therapeutics</i> , <b>2012</b> , 133, 116-23	13.9	20
29	Impaired memory following predatory stress in mice is improved by fluoxetine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2004</b> , 28, 123-8	5.5	18
28	The CRF $\beta$ receptor antagonist SSR125543 attenuates long-term cognitive deficit induced by acute inescapable stress in mice, independently from the hypothalamic pituitary adrenal axis. <i>Pharmacology Biochemistry and Behavior</i> , <b>2012</b> , 102, 415-22	3.9	17
27	The CRF $\beta$ receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: comparison with paroxetine and D-cycloserine. <i>Psychopharmacology</i> , <b>2013</b> , 228, 97-107	4.7	17
26	Differences in anxiolytic-like profile of two novel nonbenzodiazepine BZ (omega) receptor agonists on defensive behaviors of mice. <i>Pharmacology Biochemistry and Behavior</i> , <b>1999</b> , 62, 689-94	3.9	17
25	Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression. <i>Pharmacology Biochemistry and Behavior</i> , <b>2010</b> , 96, 206-10	3.9	16
24	Preclinical profile of the mixed 5-HT $1A/5$ -HT $2A$ receptor antagonist S 21,357. <i>Pharmacology Biochemistry and Behavior</i> , <b>1996</b> , 54, 509-16	3.9	15
23	Behavioural effects of selective A $2$ adenosine receptor antagonists, CGS 21197 and CGS 22706, in mice. <i>NeuroReport</i> , <b>1991</b> , 2, 139-40	1.7	15
22	Further evidence for the sleep-promoting effects of 5-HT $2A$ receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats. <i>Neuropharmacology</i> , <b>2013</b> , 70, 19-26	5.5	14
21	Awakening properties of newly discovered highly selective H $1$ receptor antagonists in rats. <i>Behavioural Brain Research</i> , <b>2012</b> , 232, 416-20	3.4	13
20	Evidence that tolerance to the anxiogenic-like effects of mCPP does not involve alteration in the function of 5-HT $2C$ receptors in the rat choroid plexus. <i>Behavioural Pharmacology</i> , <b>1994</b> , 5, 642-645	2.4	10
19	The CRF $\beta$ receptor antagonist SSR125543 prevents stress-induced long-lasting sleep disturbances in a mouse model of PTSD: comparison with paroxetine and d-cycloserine. <i>Behavioural Brain Research</i> , <b>2015</b> , 279, 41-6	3.4	9
18	Study of the modulatory activity of BZ (omega) receptor ligands on defensive behaviors in mice: evaluation of the importance of intrinsic efficacy and receptor subtype selectivity. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>1999</b> , 23, 81-98	5.5	9
17	SSR181507, a dopamine D $1$ receptor and 5-HT $2A$ receptor ligand: evidence for mixed anxiolytic- and antidepressant-like activities. <i>Pharmacology Biochemistry and Behavior</i> , <b>2011</b> , 97, 428-35	3.9	8
16	The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition. <i>Pharmacology Biochemistry and Behavior</i> , <b>2011</b> , 98, 405-11	3.9	7
15	Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and Tachykinins. <i>Current Pharmaceutical Design</i> , <b>2015</b> , 21, 3807-12	3.3	5
14	Creativity in large pharmaceutical research organizations: unleash the hungry drug hunter. <i>British Journal of Pharmacology</i> , <b>2017</b> , 174, 2152-2153	8.6	4



13	Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2013</b> , 23, 6141-5	2.9	4
12	The Mouse Defense Test Battery: A Model Measuring Different Facets of Anxiety-Related Behaviors. <i>Neuromethods</i> , <b>2011</b> , 97-106	0.4	4
11	The Mouse Defense Test Battery: An experimental model of different emotional states.75-85		4
10	Effects of intra-hippocampal injections of the NK2 receptor antagonist saredutant on the elevated plus maze, and the mouse defense test battery. <i>Neuroscience Letters</i> , <b>2010</b> , 485, 241-5	3.3	3
9	Chapter 1.1 Introduction to the handbook on fear and anxiety. <i>Handbook of Behavioral Neuroscience</i> , <b>2008</b> , 17, 3-7	0.7	3
8	Response to Roesler et al.: Neuropeptides and stress-related disorders ¶multiple targets and converging concepts. <i>Trends in Pharmacological Sciences</i> , <b>2004</b> , 25, 242-243	13.2	3
7	Long-lasting memory abnormalities following exposure to the mouse defense test battery: An animal model of PTSD. <i>Physiology and Behavior</i> , <b>2015</b> , 146, 67-72	3.5	2
6	CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodents. <i>Psychopharmacology</i> , <b>2014</b> , 231, 1289-303	4.7	2
5	Prolactin similar to ectopic pituitary isograft restores responsiveness in Snell dwarf mice. <i>NeuroReport</i> , <b>1992</b> , 3, 210-2	1.7	2
4	Subtype-selective benzodiazepine receptor ligands <b>2000</b> , 77-94		1
3	Chapter 4.6 Genetic factors underlying anxiety-behavior: A meta-analysis of rodent studies involving targeted mutations of neurotransmission genes. <i>Handbook of Behavioral Neuroscience</i> , <b>2008</b> , 17, 325-354	0.7	0
2	Mood and Anxiety Disorders. <i>Methods and Principles in Medicinal Chemistry</i> , <b>2014</b> , 193-206	0.4	
1	Nonpeptide vasopressin V1b receptor antagonists. <i>Handbook of Behavioral Neuroscience</i> , <b>2005</b> , 15, 409-421		